InnoCare Pharma (688428.SS) has signed a research collaboration and licensing agreement with Eli Lilly (LLY) worth up to about $3.35bn, the Chinese drugmaker announced.

Roche (RHHBY) has agreed a deal with Atavistik Bio worth almost $2bn, including milestone payments, to develop oral treatments for cardiovascular, kidney and metabolic diseases.

Mirum Pharmaceuticals (MIRM) said that its experimental treatment for hepatitis delta reduced levels of the virus in patients, meeting the primary goal of a late-stage study.

Merck (MRK) said that its injectable treatment for diabetic macular edema, a serious eye disease affecting people with diabetes, was as effective as the current standard of care at improving visual sharpness in a late-stage clinical trial.

The US Food and Drug Administration has approved AbbVie's (ABBV) treatment for Parkinson's disease in adults, according to the regulator's website.

BridgeBio Pharma (BBIO) expects 2027 to mark its transformation from a one-product company into a group with four globally launched therapies, according to Thomas Trimarchi, its president and chief financial officer, speaking at a Bernstein conference.

Florida's attorney-general is suing three drugmakers and three pharmacy benefit managers, alleging they worked together to inflate insulin prices and profit from the increases.

Shares in Nanexa (NANEXA) more than doubled in early trading last month after the Swedish drug-delivery company signed a global licensing agreement with Novo Nordisk (NVO) worth up to about €1.17bn ($1.33bn).

Shares in Ascendis Pharma (ASND) fell 6.1 per cent after the company said it would take back full rights to its metabolic and cardiovascular programs following the end of its collaboration with Novo Nordisk (NVO).

Shares in ADARx Pharmaceuticals (ADRX) rose 30 per cent above their offer price in Nasdaq debut trading after the late-stage gene therapy developer raised $446.3mn in an upsized US initial public offering.